138 related articles for article (PubMed ID: 3665599)
1. Tobramycin in patients with cystic fibrosis. Adjustment in dosing interval for effective treatment.
Horrevorts AM; de Witte J; Degener JE; Dzoljic-Danilovic G; Hop WC; Driessen O; Michel MF; Kerrebijn KF
Chest; 1987 Nov; 92(5):844-8. PubMed ID: 3665599
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 6 and 8 hourly tobramycin dosing intervals in treatment of pulmonary exacerbations in cystic fibrosis patients.
Winnie GB; Cooper JA; Witson J; Cowan RG; Mayer D; Lepow M
Pediatr Infect Dis J; 1991 May; 10(5):381-6. PubMed ID: 1906161
[TBL] [Abstract][Full Text] [Related]
3. Individualization of tobramycin dosage in patients with cystic fibrosis.
Hsu MC; Aguila HA; Schmidt VL; Munzenberger PJ; Kauffman RE; Polgar G
Pediatr Infect Dis; 1984; 3(6):526-9. PubMed ID: 6440126
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.
Vic P; Ategbo S; Turck D; Husson MO; Launay V; Loeuille GA; Sardet A; Deschildre A; Druon D; Arrouet-Lagande C
Arch Dis Child; 1998 Jun; 78(6):536-9. PubMed ID: 9713009
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Pseudomonas lung infection in cystic fibrosis with piperacillin plus tobramycin versus ceftazidime monotherapy: preliminary communication.
De Boeck K; Smet M; Eggermont E
Pediatr Pulmonol; 1989; 7(3):171-3. PubMed ID: 2508049
[TBL] [Abstract][Full Text] [Related]
6. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial.
Smyth A; Tan KH; Hyman-Taylor P; Mulheran M; Lewis S; Stableforth D; Prof Knox A;
Lancet; 2005 Feb 12-18; 365(9459):573-8. PubMed ID: 15708100
[TBL] [Abstract][Full Text] [Related]
7. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
8. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of tobramycin in patients with cystic fibrosis. Implications for the dosing interval.
Horrevorts AM; Degener JE; Dzoljic-Danilovic G; Michel MF; Kerrebijn KF; Driessen O; Hermans J
Chest; 1985 Aug; 88(2):260-4. PubMed ID: 4017681
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of high-dose tobramycin-carbenicillin therapy in pseudomonal infections in cystic fibrosis.
Fraser GL; Valenti AJ; Grimes GR; Corbin RP
Drug Intell Clin Pharm; 1985 Oct; 19(10):757-61. PubMed ID: 4053983
[TBL] [Abstract][Full Text] [Related]
11. Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis.
Hoogkamp-Korstanje JA; van der Laag J
J Antimicrob Chemother; 1983 Aug; 12(2):175-83. PubMed ID: 6619055
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of aerosolized tobramycin in patients with cystic fibrosis.
Ramsey BW; Dorkin HL; Eisenberg JD; Gibson RL; Harwood IR; Kravitz RM; Schidlow DV; Wilmott RW; Astley SJ; McBurnie MA
N Engl J Med; 1993 Jun; 328(24):1740-6. PubMed ID: 8497284
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients.
Lam W; Tjon J; Seto W; Dekker A; Wong C; Atenafu E; Bitnun A; Waters V; Yau Y; Solomon M; Ratjen F
J Antimicrob Chemother; 2007 Jun; 59(6):1135-40. PubMed ID: 17446242
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
Coulthard KP; Peckham DG; Conway SP; Smith CA; Bell J; Turnidge J
J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
[TBL] [Abstract][Full Text] [Related]
16. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
Cheer SM; Waugh J; Noble S
Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
[TBL] [Abstract][Full Text] [Related]
17. Tobramycin in treatment of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.
Crozier DN; Khan SR
J Infect Dis; 1976 Aug; 134 Suppl():S187-90. PubMed ID: 823275
[TBL] [Abstract][Full Text] [Related]
18. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis.
Whitehead A; Conway SP; Etherington C; Caldwell NA; Setchfield N; Bogle S
Eur Respir J; 2002 Feb; 19(2):303-9. PubMed ID: 11866010
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis.
Brigg Turner R; Elbarbry F; Biondo L
J Chemother; 2016 Aug; 28(4):304-7. PubMed ID: 26430825
[TBL] [Abstract][Full Text] [Related]
20. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
